Article(id=1210516652110770537, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1210516638089212895, articleNumber=null, orderNo=null, doi=10.16438/j.0513-4870.2022-0134, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=research-article, receivedDate=1643212800000, receivedDateStr=2022-01-27, revisedDate=1648224000000, revisedDateStr=2022-03-26, acceptedDate=null, acceptedDateStr=null, onlineDate=1766539260174, onlineDateStr=2025-12-24, pubDate=1662912000000, pubDateStr=2022-09-12, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1766539260174, onlineIssueDateStr=2025-12-24, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1766539260174, creator=13701087609, updateTime=1766539260174, updator=13701087609, issue=Issue{id=1210516638089212895, tenantId=1146029695717560320, journalId=1189982191388893191, year='2022', volume='57', issue='9', pageStart='1', pageEnd='2888', issueExtLink='null', onlineDate='null', pubDate='null', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1766539256832, creator=13701087609, updateTime=1766539546411, updator=13701087609, preIssue=null, nextIssue=null, ext={EN=IssueExt(id=1210517852726096743, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1210516638089212895, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1210517852726096744, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1210516638089212895, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null}, startPage=2682, endPage=2695, ext={EN=ArticleExt(id=1210516652635058581, articleId=1210516652110770537, tenantId=1146029695717560320, journalId=1189982191388893191, language=EN, title=Progress on research and development of drug for chronic kidney disease and related comorbidities, columnId=1190335348648547107, journalTitle=Acta Pharmaceutica Sinica, columnName=Reviews, runingTitle=null, highlight=null, articleAbstract=

Chronic kidney disease (CKD) is a progressive disease with many complications (eg, cardiovascular disease and acidosis and anemia) and high morbidity and mortality occurs in the population. There is no cure for this disease, current treatments including renin-angiotensin-aldosterone pathway inhibitors and sodium-glucose co-transporter 2 inhibitors can only delay the progression to end-stage renal disease. With the identification of more key factors and mechanisms in CKD development, new potential therapeutic approaches for CKD can be developed. This review summarizes the mainstays of therapy and strategies for CKD and related comorbidities to support the development of novel treatments.

, correspAuthors=Wen-sheng ZHENG, authorNote=null, correspAuthorsNote=null, copyrightStatement=Copyright ©2022 Acta Pharmaceutica Sinica. All rights reserved., copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=Yi-ge YANG, He LI, Xiu-li ZHANG, Xiao-chuan TAN, Yu-jia ZHANG, Wen-sheng ZHENG), CN=ArticleExt(id=1210516653645885935, articleId=1210516652110770537, tenantId=1146029695717560320, journalId=1189982191388893191, language=CN, title=慢性肾病及相关并发症治疗药物研究进展, columnId=1190335349655180086, journalTitle=药学学报, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

慢性肾病(chronic kidney disease, CKD) 是一种伴随着多种并发症(心血管疾病、代谢性酸中毒和贫血等) 的进行性疾病, 在人群中有着较高的发病率和死亡率。目前的主要治疗药物包括肾素-血管紧张素-醛固酮通路抑制剂及钠-葡萄糖共转运蛋白2抑制剂, 都只能延缓CKD向终末期肾病的进展, 而不能彻底治疗CKD。随着更多在CKD进展中起到关键作用的通路被发现, 新的有前景的治疗方法也有望被研发出来。本文对CKD和其并发症的主要疗法及新兴疗法进行了总结, 以期为CKD新疗法的研发提供支持。

, correspAuthors=郑稳生, authorNote=null, correspAuthorsNote=, copyrightStatement=版权所有©《药学学报》编辑部2022, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=/iUm6s0avH4jOy+5vxeGmA==, magXml=UIiQ+Az+3dKzinhWUtnssg==, pdfUrl=null, pdf=MpFGl6vkBJV7XqwlD1zSFw==, pdfFileSize=861605, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=pIkI256BoZSA8FnKadbbfw==, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=杨一歌, 李鹤, 张秀立, 谭晓川, 张宇佳, 郑稳生)}, authors=[Author(id=1210516654329557556, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210516654493135427, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516654329557556, language=EN, stringName=Yi-ge YANG, firstName=Yi-ge, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, 2}, address=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Tianjin University, Tianjin 100072, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210516654635741775, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516654329557556, language=CN, stringName=杨一歌, firstName=一歌, middleName=null, lastName=杨, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, 2}, address=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050
2.天津大学, 天津 100072, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210516653994013198, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, xref=null, ext=[AuthorCompanyExt(id=1210516654006596113, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1210516654023373330, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050)]), AuthorCompany(id=1210516654186951203, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, xref=null, ext=[AuthorCompanyExt(id=1210516654195339814, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516654186951203, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2. Tianjin University, Tianjin 100072, China), AuthorCompanyExt(id=1210516654203728422, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516654186951203, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.天津大学, 天津 100072)])]), Author(id=1210516654736405077, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210516654862234209, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516654736405077, language=EN, stringName=He LI, firstName=He, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210516654988063341, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516654736405077, language=CN, stringName=李鹤, firstName=鹤, middleName=null, lastName=李, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210516653994013198, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, xref=null, ext=[AuthorCompanyExt(id=1210516654006596113, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1210516654023373330, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050)])]), Author(id=1210516655109698170, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210516655231332994, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516655109698170, language=EN, stringName=Xiu-li ZHANG, firstName=Xiu-li, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210516655365550740, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516655109698170, language=CN, stringName=张秀立, firstName=秀立, middleName=null, lastName=张, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210516653994013198, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, xref=null, ext=[AuthorCompanyExt(id=1210516654006596113, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1210516654023373330, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050)])]), Author(id=1210516655600431777, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210516655789175468, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516655600431777, language=EN, stringName=Xiao-chuan TAN, firstName=Xiao-chuan, middleName=null, lastName=TAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210516655919198910, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516655600431777, language=CN, stringName=谭晓川, firstName=晓川, middleName=null, lastName=谭, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210516653994013198, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, xref=null, ext=[AuthorCompanyExt(id=1210516654006596113, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1210516654023373330, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050)])]), Author(id=1210516656040833739, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210516656175051480, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516656040833739, language=EN, stringName=Yu-jia ZHANG, firstName=Yu-jia, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210516656309269222, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516656040833739, language=CN, stringName=张宇佳, firstName=宇佳, middleName=null, lastName=张, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210516653994013198, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, xref=null, ext=[AuthorCompanyExt(id=1210516654006596113, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1210516654023373330, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050)])]), Author(id=1210516656443486963, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=zhengwensheng@imm.ac.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1210516656569316098, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516656443486963, language=EN, stringName=Wen-sheng ZHENG, firstName=Wen-sheng, middleName=null, lastName=ZHENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, *}, address=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210516656682562318, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, authorId=1210516656443486963, language=CN, stringName=郑稳生, firstName=稳生, middleName=null, lastName=郑, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, *}, address=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210516653994013198, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, xref=null, ext=[AuthorCompanyExt(id=1210516654006596113, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1210516654023373330, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050)])])], keywords=[Keyword(id=1210516656930026275, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=EN, orderNo=1, keyword=chronic kidney disease), Keyword(id=1210516657051661100, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=EN, orderNo=2, keyword=comorbidity), Keyword(id=1210516657181684530, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=EN, orderNo=3, keyword=drug development), Keyword(id=1210516657336873789, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=EN, orderNo=4, keyword=end-stage renal disease), Keyword(id=1210516657466897226, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=EN, orderNo=5, keyword=clinical trial drug), Keyword(id=1210516657584337748, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=CN, orderNo=1, keyword=慢性肾病), Keyword(id=1210516657752109921, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=CN, orderNo=2, keyword=并发症), Keyword(id=1210516657886327659, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=CN, orderNo=3, keyword=药物研发), Keyword(id=1210516657982796660, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=CN, orderNo=4, keyword=终末期肾病), Keyword(id=1210516658087654268, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=CN, orderNo=5, keyword=临床试验药物)], refs=[Reference(id=1210516658788103082, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S0140-6736(21)00519-5, pmid=null, pmcid=null, year=2021, volume=398, issue=null, pageStart=786, pageEnd=802, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=Lancet, refType=null, unstructuredReference=Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease[J]. Lancet, 2021, 398: 786-802., articleTitle=Chronic kidney disease, refAbstract=null), Reference(id=1210516658892960688, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1038/nrd.2016.67, pmid=null, pmcid=null, year=2016, volume=15, issue=null, pageStart=568, pageEnd=588, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=Nat Rev Drug Discov, refType=null, unstructuredReference=Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease[J]. Nat Rev Drug Discov, 2016, 15: 568-588., articleTitle=The next generation of therapeutics for chronic kidney disease, refAbstract=null), Reference(id=1210516659002012598, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1111/j.1600-6143.2012.04101.x, pmid=null, pmcid=null, year=2012, volume=12, issue=null, pageStart=2437, pageEnd=2445, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=Am J Transplant, refType=null, unstructuredReference=Weiner DE, Carpenter MA, Levy AS, et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial[J]. Am J Transplant, 2012, 12: 2437-2445., articleTitle=Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial, refAbstract=null), Reference(id=1210516659123647421, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.7326/0003-4819-158-11-201306040-00007, pmid=null, pmcid=null, year=2013, volume=158, issue=null, pageStart=825, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=Ann Intern Med, refType=null, unstructuredReference=Stevens PE, Levin A, Kidney DIG. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158: 825., articleTitle=Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline, refAbstract=null), Reference(id=1210516659266253765, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S0140-6736(20)30045-3, pmid=null, pmcid=null, year=2020, volume=395, issue=null, pageStart=709, pageEnd=733, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=Lancet, refType=null, unstructuredReference=Bikbov B, Purcell C, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017[J]. Lancet, 2020, 395: 709-733., articleTitle=Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017, refAbstract=null), Reference(id=1210516659404665807, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.kint.2018.04.011, pmid=null, pmcid=null, year=2018, volume=94, issue=null, pageStart=567, pageEnd=581, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=Kidney Int, refType=null, unstructuredReference=Xie Y, Bowe B, Mokdad AH, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016[J]. Kidney Int, 2018, 94: 567-581., articleTitle=Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016, refAbstract=null), Reference(id=1210516659517912020, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2018050531, pmid=null, pmcid=null, year=2019, volume=30, issue=null, pageStart=127, pageEnd=135, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=McCullough KP, Morgenstern H, Saran R, et al. Projecting ESRD incidence and prevalence in the United States through 2030[J]. J Am Soc Nephrol, 2019, 30: 127-135., articleTitle=Projecting ESRD incidence and prevalence in the United States through 2030, refAbstract=null), Reference(id=1210516659626963930, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1097/MNH.0000000000000670, pmid=null, pmcid=null, year=2021, volume=30, issue=null, pageStart=97, pageEnd=107, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=Curr Opin Nephrol Hypertens, refType=null, unstructuredReference=Zarantonello D, Rhee CM, Kalantar-Zadeh K, et al. Novel conservative management of chronic kidney disease via dialysis-free interventions[J]. Curr Opin Nephrol Hypertens, 2021, 30: 97-107., articleTitle=Novel conservative management of chronic kidney disease via dialysis-free interventions, refAbstract=null), Reference(id=1210516659769570272, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2017121273, pmid=null, pmcid=null, year=2018, volume=29, issue=null, pageStart=2169, pageEnd=2177, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Tamura MK, Desai M, Kapphahn KI, et al. Dialysis versus medical management at different ages and levels of kidney function in veterans with advanced CKD[J]. J Am Soc Nephrol, 2018, 29: 2169-2177., articleTitle=Dialysis versus medical management at different ages and levels of kidney function in veterans with advanced CKD, refAbstract=null), Reference(id=1210516659920565221, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1172/JCI112521, pmid=null, pmcid=null, year=1986, volume=77, issue=null, pageStart=1925, pageEnd=1930, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=J Clin Invest, refType=null, unstructuredReference=Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension[J]. J Clin Invest, 1986, 77: 1925-1930., articleTitle=Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension, refAbstract=null), Reference(id=1210516660079948779, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.V1261315, pmid=null, pmcid=null, year=2001, volume=12, issue=null, pageStart=1315, pageEnd=1325, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Anonymous. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation[J]. J Am Soc Nephrol, 2001, 12: 1315-1325., articleTitle=Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation, refAbstract=null), Reference(id=1210516660243526643, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa011303, pmid=null, pmcid=null, year=2001, volume=345, issue=null, pageStart=851, pageEnd=860, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[J]. New Engl J Med, 2001, 345: 851-860., articleTitle=Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, refAbstract=null), Reference(id=1210516660360967160, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa011161, pmid=null, pmcid=null, year=2001, volume=345, issue=null, pageStart=861, pageEnd=869, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J]. New Engl J Med, 2001, 345: 861-869., articleTitle=Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, refAbstract=null), Reference(id=1210516660482601983, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa011489, pmid=null, pmcid=null, year=2001, volume=345, issue=null, pageStart=870, pageEnd=878, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J]. New Engl J Med, 2001, 345: 870-878., articleTitle=The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, refAbstract=null), Reference(id=1210516660612624391, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1053/j.ackd.2011.04.001, pmid=null, pmcid=null, year=2011, volume=18, issue=null, pageStart=290, pageEnd=299, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=Adv Chronic Kidney Dis, refType=null, unstructuredReference=Heerspink HJ. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway[J]. Adv Chronic Kidney Dis, 2011, 18: 290-299., articleTitle=Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway, refAbstract=null), Reference(id=1210516660721676297, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1097/00004872-200201000-00018, pmid=null, pmcid=null, year=2002, volume=20, issue=null, pageStart=125, pageEnd=130, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=J Hypertens, refType=null, unstructuredReference=Ferrari P, Marti HP, Pfister M, et al. Additive antiproteinuric effect of combined ACE inhibition and angiotensin Ⅱ receptor blockade[J]. J Hypertens, 2002, 20: 125-130., articleTitle=Additive antiproteinuric effect of combined ACE inhibition and angiotensin Ⅱ receptor blockade, refAbstract=null), Reference(id=1210516660847505423, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa1303154, pmid=null, pmcid=null, year=2013, volume=369, issue=null, pageStart=1892, pageEnd=1903, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy[J]. New Engl J Med, 2013, 369: 1892-1903., articleTitle=Combined angiotensin inhibition for the treatment of diabetic nephropathy, refAbstract=null), Reference(id=1210516660977528855, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa0801317, pmid=null, pmcid=null, year=2008, volume=358, issue=null, pageStart=1547, pageEnd=1559, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events[J]. New Engl J Med, 2008, 358: 1547-1559., articleTitle=Telmisartan, ramipril, or both in patients at high risk for vascular events, refAbstract=null), Reference(id=1210516661132718106, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.2337/dc13-0387, pmid=null, pmcid=null, year=2013, volume=36, issue=null, pageStart=3169, pageEnd=3176, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=Diabetes Care, refType=null, unstructuredReference=DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes[J]. Diabetes Care, 2013, 36: 3169-3176., articleTitle=Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes, refAbstract=null), Reference(id=1210516661250158622, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1186/1475-2840-13-28, pmid=null, pmcid=null, year=2014, volume=13, issue=null, pageStart=28, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=Cardiovasc Diabetol, refType=null, unstructuredReference=Cherney D, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus[J]. Cardiovasc Diabetol, 2014, 13: 28., articleTitle=The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus, refAbstract=null), Reference(id=1210516661447290918, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.3390/ijms18051083, pmid=null, pmcid=null, year=2017, volume=18, issue=null, pageStart=1083, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=Int J Mol Sci, refType=null, unstructuredReference=Kawanami D, Matoba K, Takeda Y, et al. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy[J]. Int J Mol Sci, 2017, 18: 1083., articleTitle=SGLT2 inhibitors as a therapeutic option for diabetic nephropathy, refAbstract=null), Reference(id=1210516661581508654, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1007/s00125-016-4008-2, pmid=null, pmcid=null, year=2016, volume=59, issue=null, pageStart=1860, pageEnd=1870, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=Diabetologia, refType=null, unstructuredReference=Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes[J]. Diabetologia, 2016, 59: 1860-1870., articleTitle=The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes, refAbstract=null), Reference(id=1210516661732503605, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S2213-8587(17)30182-1, pmid=null, pmcid=null, year=2017, volume=5, issue=null, pageStart=610, pageEnd=621, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=Lancet Diabetes Endocrinol, refType=null, unstructuredReference=Cherney D, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2017, 5: 610-621., articleTitle=Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial, refAbstract=null), Reference(id=1210516661841555513, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2016030278, pmid=null, pmcid=null, year=2017, volume=28, issue=null, pageStart=368, pageEnd=375, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Heerspink H, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects[J]. J Am Soc Nephrol, 2017, 28: 368-375., articleTitle=Canagliflozin slows progression of renal function decline independently of glycemic effects, refAbstract=null), Reference(id=1210516661963190332, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S2213-8587(21)00243-6, pmid=null, pmcid=null, year=2021, volume=9, issue=null, pageStart=755, pageEnd=766, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=Lancet Diabetes Endocrinol, refType=null, unstructuredReference=Jongs N, Greene T, Chertow GM, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial[J]. Lancet Diabetes Endocrinol, 2021, 9: 755-766., articleTitle=Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial, refAbstract=null), Reference(id=1210516662034493506, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.jchf.2021.06.017, pmid=null, pmcid=null, year=2021, volume=9, issue=null, pageStart=807, pageEnd=820, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=JACC Heart Fail, refType=null, unstructuredReference=McMurray J, Wheeler DC, Stefansson BV, et al. Effects of dapagliflozin in patients with kidney disease, with and without heart failure[J]. JACC Heart Fail, 2021, 9: 807-820., articleTitle=Effects of dapagliflozin in patients with kidney disease, with and without heart failure, refAbstract=null), Reference(id=1210516662118379591, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1093/ndt/gfz290, pmid=null, pmcid=null, year=2020, volume=35, issue=null, pageStart=274, pageEnd=282, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=Nephrol Dial Transplant, refType=null, unstructuredReference=Heerspink H, Stefansson BV, Chertow GM, et al. Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial[J]. Nephrol Dial Transplant, 2020, 35: 274-282., articleTitle=Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial, refAbstract=null), Reference(id=1210516662240014415, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1111/j.1523-1755.2004.00701.x, pmid=null, pmcid=null, year=2004, volume=66, issue=null, pageStart=1, pageEnd=9, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=Kidney Int, refType=null, unstructuredReference=Hollenberg NK. Aldosterone in the development and progression of renal injury[J]. Kidney Int, 2004, 66: 1-9., articleTitle=Aldosterone in the development and progression of renal injury, refAbstract=null), Reference(id=1210516662370037844, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMp048144, pmid=null, pmcid=null, year=2004, volume=351, issue=null, pageStart=526, pageEnd=528, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=McMurray J, O'Meara E. Treatment of heart failure with spironolactone - trial and tribulations[J]. New Engl J Med, 2004, 351: 526-528., articleTitle=Treatment of heart failure with spironolactone - trial and tribulations, refAbstract=null), Reference(id=1210516662483284061, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1186/s12882-019-1348-4, pmid=null, pmcid=null, year=2019, volume=20, issue=null, pageStart=171, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=BMC Nephrol, refType=null, unstructuredReference=Blankenburg M, Fett AK, Eisenring S, et al. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study[J]. BMC Nephrol, 2019, 20: 171., articleTitle=Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study, refAbstract=null), Reference(id=1210516662583947363, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1093/eurheartj/eht187, pmid=null, pmcid=null, year=2013, volume=34, issue=null, pageStart=2453, pageEnd=2463, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=Eur Heart J, refType=null, unstructuredReference=Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial[J]. Eur Heart J, 2013, 34: 2453-2463., articleTitle=Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial, refAbstract=null), Reference(id=1210516662709776489, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=null, pmid=null, pmcid=null, year=2008, volume=2, issue=null, pageStart=823, pageEnd=843, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=Biologics, refType=null, unstructuredReference=Fervenza FC, Torra R, Warnock DG. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease[J]. Biologics, 2008, 2: 823-843., articleTitle=Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease, refAbstract=null), Reference(id=1210516662831411314, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa1510198, pmid=null, pmcid=null, year=2016, volume=375, issue=null, pageStart=545, pageEnd=555, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat[J]. New Engl J Med, 2016, 375: 545-555., articleTitle=Treatment of Fabry's disease with the pharmacologic chaperone migalastat, refAbstract=null), Reference(id=1210516662944657525, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1111/j.1523-1755.2004.00873.x, pmid=null, pmcid=null, year=2004, volume=66, issue=null, pageStart=1199, pageEnd=1205, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=Kidney Int, refType=null, unstructuredReference=Troyanov S, Wall CA, Miller JA, et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission[J]. Kidney Int, 2004, 66: 1199-1205., articleTitle=Idiopathic membranous nephropathy: definition and relevance of a partial remission, refAbstract=null), Reference(id=1210516663049515129, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.2215/CJN.11761116, pmid=null, pmcid=null, year=2017, volume=12, issue=null, pageStart=983, pageEnd=997, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=Clin J Am Soc Nephrol, refType=null, unstructuredReference=Couser WG. Primary membranous nephropathy[J]. Clin J Am Soc Nephrol, 2017, 12: 983-997., articleTitle=Primary membranous nephropathy, refAbstract=null), Reference(id=1210516663166955647, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa0810457, pmid=null, pmcid=null, year=2009, volume=361, issue=null, pageStart=11, pageEnd=21, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Beck LH, Bonegio R, Lambeau G, et al. M-Type phospholipase A (sub 2) receptor as target antigen in idiopathic membranous nephropathy[J]. New Engl J Med, 2009, 361: 11-21., articleTitle=M-Type phospholipase A (sub 2) receptor as target antigen in idiopathic membranous nephropathy, refAbstract=null), Reference(id=1210516663267618951, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2010111125, pmid=null, pmcid=null, year=2011, volume=22, issue=null, pageStart=1543, pageEnd=1550, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Beck LH, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA(2)R autoantibodies predicts response in membranous nephropathy[J]. J Am Soc Nephrol, 2011, 22: 1543-1550., articleTitle=Rituximab-induced depletion of anti-PLA(2)R autoantibodies predicts response in membranous nephropathy, refAbstract=null), Reference(id=1210516663376670857, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa1814427, pmid=null, pmcid=null, year=2019, volume=381, issue=null, pageStart=36, pageEnd=46, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy[J]. New Engl J Med, 2019, 381: 36-46., articleTitle=Rituximab or cyclosporine in the treatment of membranous nephropathy, refAbstract=null), Reference(id=1210516663477334155, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2016040449, pmid=null, pmcid=null, year=2017, volume=28, issue=null, pageStart=348, pageEnd=358, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up[J]. J Am Soc Nephrol, 2017, 28: 348-358., articleTitle=Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up, refAbstract=null), Reference(id=1210516663607357584, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2012020181, pmid=null, pmcid=null, year=2012, volume=23, issue=null, pageStart=1416, pageEnd=1425, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2012, 23: 1416-1425., articleTitle=Rituximab in idiopathic membranous nephropathy, refAbstract=null), Reference(id=1210516663687049361, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.2215/CJN.05080610, pmid=null, pmcid=null, year=2010, volume=5, issue=null, pageStart=2188, pageEnd=2198, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=Clin J Am Soc Nephrol, refType=null, unstructuredReference=Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study[J]. Clin J Am Soc Nephrol, 2010, 5: 2188-2198., articleTitle=Rituximab therapy in idiopathic membranous nephropathy: a 2-year study, refAbstract=null), Reference(id=1210516663804489879, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1038/sj.ki.5002628, pmid=null, pmcid=null, year=2008, volume=73, issue=null, pageStart=117, pageEnd=125, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=Kidney Int, refType=null, unstructuredReference=Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy[J]. Kidney Int, 2008, 73: 117-125., articleTitle=Rituximab treatment of idiopathic membranous nephropathy, refAbstract=null), Reference(id=1210516663875793047, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1111/bjh.15790, pmid=null, pmcid=null, year=2019, volume=185, issue=null, pageStart=297, pageEnd=310, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=Br J Haematol, refType=null, unstructuredReference=Socie G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis[J]. Br J Haematol, 2019, 185: 297-310., articleTitle=Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis, refAbstract=null), Reference(id=1210516663976456349, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1093/ckj/sfaa096, pmid=null, pmcid=null, year=2021, volume=14, issue=null, pageStart=1173, pageEnd=1180, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=Clin Kidney J, refType=null, unstructuredReference=Portoles J, Huerta A, Arjona E, et al. Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study[J]. Clin Kidney J, 2021, 14: 1173-1180., articleTitle=Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study, refAbstract=null), Reference(id=1210516664077119646, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.3390/ijms21239064, pmid=null, pmcid=null, year=2020, volume=21, issue=null, pageStart=9064, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=Int J Mol Sci, refType=null, unstructuredReference=Maixnerova D, Tesar V. Emerging modes of treatment of IgA nephropathy[J]. Int J Mol Sci, 2020, 21: 9064., articleTitle=Emerging modes of treatment of IgA nephropathy, refAbstract=null), Reference(id=1210516664144228513, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1053/j.ajkd.2013.06.002, pmid=null, pmcid=null, year=2013, volume=62, issue=null, pageStart=403, pageEnd=441, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=Am J Kidney Dis, refType=null, unstructuredReference=Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis[J]. Am J Kidney Dis, 2013, 62: 403-441., articleTitle=KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis, refAbstract=null), Reference(id=1210516664215531684, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1001/jama.2017.9362, pmid=null, pmcid=null, year=2017, volume=318, issue=null, pageStart=432, pageEnd=442, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=JAMA, refType=null, unstructuredReference=Lv JC, Zhang H, Wong MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy the TESTING randomized clinical trial[J]. JAMA, 2017, 318: 432-442., articleTitle=Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy the TESTING randomized clinical trial, refAbstract=null), Reference(id=1210516664282640551, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S0140-6736(18)32782-X, pmid=null, pmcid=null, year=2019, volume=393, issue=null, pageStart=919, pageEnd=935, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=Lancet, refType=null, unstructuredReference=Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease[J]. Lancet, 2019, 393: 919-935., articleTitle=Autosomal dominant polycystic kidney disease, refAbstract=null), Reference(id=1210516664366526633, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2007060688, pmid=null, pmcid=null, year=2008, volume=19, issue=null, pageStart=102, pageEnd=108, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Wang XF, Wu YH, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease[J]. J Am Soc Nephrol, 2008, 19: 102-108., articleTitle=Vasopressin directly regulates cyst growth in polycystic kidney disease, refAbstract=null), Reference(id=1210516664454607023, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa1205511, pmid=null, pmcid=null, year=2012, volume=367, issue=null, pageStart=2407, pageEnd=2418, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease[J]. New Engl J Med, 2012, 367: 2407-2418., articleTitle=Tolvaptan in patients with autosomal dominant polycystic kidney disease, refAbstract=null), Reference(id=1210516664567853234, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa1710030, pmid=null, pmcid=null, year=2017, volume=377, issue=null, pageStart=1930, pageEnd=1942, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease[J]. New Engl J Med, 2017, 377: 1930-1942., articleTitle=Tolvaptan in later-stage autosomal dominant polycystic kidney disease, refAbstract=null), Reference(id=1210516664643350711, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S2213-8587(19)30249-9, pmid=null, pmcid=null, year=2019, volume=7, issue=null, pageStart=776, pageEnd=785, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=Lancet Diabetes Endocrinol, refType=null, unstructuredReference=Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7: 776-785., articleTitle=Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, refAbstract=null), Reference(id=1210516664731431102, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1161/JAHA.119.014908, pmid=null, pmcid=null, year=2020, volume=9, issue=null, pageStart=e014908, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=J Am Heart Assoc, refType=null, unstructuredReference=Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis[J]. J Am Heart Assoc, 2020, 9: e014908., articleTitle=Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis, refAbstract=null), Reference(id=1210516664844677315, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1161/CIRCULATIONAHA.120.051685, pmid=null, pmcid=null, year=2021, volume=143, issue=null, pageStart=310, pageEnd=321, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=Circulation, refType=null, unstructuredReference=Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function insights from EMPEROR-reduced[J]. Circulation, 2021, 143: 310-321., articleTitle=Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function insights from EMPEROR-reduced, refAbstract=null), Reference(id=1210516664924369090, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.2174/1389557521666210616161728, pmid=null, pmcid=null, year=2021, volume=21, issue=null, pageStart=3052, pageEnd=3061, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=Mini Rev Med Chem, refType=null, unstructuredReference=Gosik R, Danel K. The rising risk of chronic kidney disease (CKD) and how it is dealt with: a review of current and potential phosphate binders (PB)[J]. Mini Rev Med Chem, 2021, 21: 3052-3061., articleTitle=The rising risk of chronic kidney disease (CKD) and how it is dealt with: a review of current and potential phosphate binders (PB), refAbstract=null), Reference(id=1210516665037615304, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.2147/IJNRD.S191156, pmid=null, pmcid=null, year=2019, volume=12, issue=null, pageStart=263, pageEnd=276, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=Int J Nephrol Renovasc Dis, refType=null, unstructuredReference=Waziri B, Duarte R, Naicker S. Chronic kidney disease-mineral and bone disorder (CKD-MBD): current perspectives[J]. Int J Nephrol Renovasc Dis, 2019, 12: 263-276., articleTitle=Chronic kidney disease-mineral and bone disorder (CKD-MBD): current perspectives, refAbstract=null), Reference(id=1210516665113112779, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.7326/M16-0273, pmid=null, pmcid=null, year=2016, volume=165, issue=null, pageStart=473, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=Ann Intern Med, refType=null, unstructuredReference=Murphy D, McCulloch CE, Lin F, et al. Trends in prevalence of chronic kidney disease in the United States[J]. Ann Intern Med, 2016, 165: 473., articleTitle=Trends in prevalence of chronic kidney disease in the United States, refAbstract=null), Reference(id=1210516665196998865, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.ekir.2020.11.034, pmid=null, pmcid=null, year=2021, volume=6, issue=null, pageStart=624, pageEnd=635, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=Kidney Int Rep, refType=null, unstructuredReference=Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients[J]. Kidney Int Rep, 2021, 6: 624-635., articleTitle=Roxadustat for CKD-related anemia in non-dialysis patients, refAbstract=null), Reference(id=1210516665280884948, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.kisu.2020.12.006, pmid=null, pmcid=null, year=2021, volume=11, issue=null, pageStart=26, pageEnd=34, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=Kidney Int Suppl, refType=null, unstructuredReference=Raichoudhury R, Spinowitz BS. Treatment of anemia in difficult-to-manage patients with chronic kidney disease[J]. Kidney Int Suppl, 2021, 11: 26-34., articleTitle=Treatment of anemia in difficult-to-manage patients with chronic kidney disease, refAbstract=null), Reference(id=1210516665347993818, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1089/dia.2019.0212, pmid=null, pmcid=null, year=2019, volume=21, issue=null, pageStart=713, pageEnd=720, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=Diabetes Technol Ther, refType=null, unstructuredReference=Maruyama T, Takashima H, Oguma H, et al. Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease[J]. Diabetes Technol Ther, 2019, 21: 713-720., articleTitle=Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease, refAbstract=null), Reference(id=1210516665423491292, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.jdiacomp.2020.107729, pmid=null, pmcid=null, year=2020, volume=34, issue=null, pageStart=107729, pageEnd=null, url=null, language=null, rfNumber=[61], rfOrder=60, authorNames=null, journalName=J Diabetes Complicat, refType=null, unstructuredReference=Stefansson BV, Heerspink H, Wheeler DC, et al. Correction of anemia by dapagliflozin in patients with type 2 diabetes[J]. J Diabetes Complicat, 2020, 34: 107729., articleTitle=Correction of anemia by dapagliflozin in patients with type 2 diabetes, refAbstract=null), Reference(id=1210516665507377376, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1159/000516371, pmid=null, pmcid=null, year=2021, volume=7, issue=null, pageStart=452, pageEnd=467, url=null, language=null, rfNumber=[62], rfOrder=61, authorNames=null, journalName=Kidney Dis, refType=null, unstructuredReference=Adamczak M, Surma S. Metabolic acidosis in patients with CKD: epidemiology, pathogenesis, and treatment[J]. Kidney Dis, 2021, 7: 452-467., articleTitle=Metabolic acidosis in patients with CKD: epidemiology, pathogenesis, and treatment, refAbstract=null), Reference(id=1210516665595457763, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.3389/fphar.2021.643128, pmid=null, pmcid=null, year=2021, volume=12, issue=null, pageStart=643128, pageEnd=null, url=null, language=null, rfNumber=[63], rfOrder=62, authorNames=null, journalName=Front Pharmacol, refType=null, unstructuredReference=Liu WL, Li LL, Zhang XM, et al. Efficacy and safety of veverimer in the treatment of metabolic acidosis caused by chronic kidney disease: a meta-analysis[J]. Front Pharmacol, 2021, 12: 643128., articleTitle=Efficacy and safety of veverimer in the treatment of metabolic acidosis caused by chronic kidney disease: a meta-analysis, refAbstract=null), Reference(id=1210516665704509671, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1080/17512433.2021.1932460, pmid=null, pmcid=null, year=2021, volume=14, issue=null, pageStart=1055, pageEnd=1064, url=null, language=null, rfNumber=[64], rfOrder=63, authorNames=null, journalName=Expert Rev Clin Pharmacol, refType=null, unstructuredReference=Rastogi A, Hanna RM, Mkrttchyan A, et al. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent[J]. Expert Rev Clin Pharmacol, 2021, 14: 1055-1064., articleTitle=Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent, refAbstract=null), Reference(id=1210516665796784362, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1186/cc11872, pmid=null, pmcid=null, year=2012, volume=16, issue=null, pageStart=R225, pageEnd=null, url=null, language=null, rfNumber=[65], rfOrder=64, authorNames=null, journalName=Crit Care, refType=null, unstructuredReference=An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality[J]. Crit Care, 2012, 16: R225., articleTitle=Severe hyperkalemia requiring hospitalization: predictors of mortality, refAbstract=null), Reference(id=1210516665884864751, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1093/ndt/gfz285, pmid=null, pmcid=null, year=2021, volume=36, issue=null, pageStart=137, pageEnd=150, url=null, language=null, rfNumber=[66], rfOrder=65, authorNames=null, journalName=Nephrol Dial Transpl, refType=null, unstructuredReference=Roger SD, Lavin PT, Lerma EV, et al. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, phase 3 study[J]. Nephrol Dial Transpl, 2021, 36: 137-150., articleTitle=Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, phase 3 study, refAbstract=null), Reference(id=1210516665972945135, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1159/000368940, pmid=null, pmcid=null, year=2015, volume=39, issue=null, pageStart=84, pageEnd=92, url=null, language=null, rfNumber=[67], rfOrder=66, authorNames=null, journalName=Blood Purif, refType=null, unstructuredReference=Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease[J]. Blood Purif, 2015, 39: 84-92., articleTitle=Update on inflammation in chronic kidney disease, refAbstract=null), Reference(id=1210516666040054002, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1089/jir.2008.0027, pmid=null, pmcid=null, year=2009, volume=29, issue=null, pageStart=313, pageEnd=326, url=null, language=null, rfNumber=[68], rfOrder=67, authorNames=null, journalName=J Interf Cytok Res, refType=null, unstructuredReference=Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview[J]. J Interf Cytok Res, 2009, 29: 313-326., articleTitle=Monocyte chemoattractant protein-1 (MCP-1): an overview, refAbstract=null), Reference(id=1210516666098774261, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S2213-8587(15)00261-2, pmid=null, pmcid=null, year=2015, volume=3, issue=null, pageStart=687, pageEnd=696, url=null, language=null, rfNumber=[69], rfOrder=68, authorNames=null, journalName=Lancet Diabetes Endocrinol, refType=null, unstructuredReference=de Zeeuw D, Bekker P, Henkel E, et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial[J]. Lancet Diabetes Endocrinol, 2015, 3: 687-696., articleTitle=The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial, refAbstract=null), Reference(id=1210516666170077433, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.ekir.2018.07.010, pmid=null, pmcid=null, year=2018, volume=3, issue=null, pageStart=1316, pageEnd=1327, url=null, language=null, rfNumber=[70], rfOrder=69, authorNames=null, journalName=Kidney Int Rep, refType=null, unstructuredReference=Gale JD, Gilbert S, Blumenthal S, et al. Effect of PF-04634817, an oral CCR2/5 chemokine receptor antagonist, on albuminuria in adults with overt diabetic nephropathy[J]. Kidney Int Rep, 2018, 3: 1316-1327., articleTitle=Effect of PF-04634817, an oral CCR2/5 chemokine receptor antagonist, on albuminuria in adults with overt diabetic nephropathy, refAbstract=null), Reference(id=1210516666249769213, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.immuni.2012.03.013, pmid=null, pmcid=null, year=2012, volume=36, issue=null, pageStart=503, pageEnd=514, url=null, language=null, rfNumber=[71], rfOrder=70, authorNames=null, journalName=Immunity, refType=null, unstructuredReference=Stark GR, Darnell JE. The JAK-STAT pathway at twenty[J]. Immunity, 2012, 36: 503-514., articleTitle=The JAK-STAT pathway at twenty, refAbstract=null), Reference(id=1210516666304295169, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.2337/db08-1328, pmid=null, pmcid=null, year=2009, volume=58, issue=null, pageStart=469, pageEnd=477, url=null, language=null, rfNumber=[72], rfOrder=71, authorNames=null, journalName=Diabetes, refType=null, unstructuredReference=Berthier CC, Zhang H, Schin M, et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy[J]. Diabetes, 2009, 58: 469-477., articleTitle=Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy, refAbstract=null), Reference(id=1210516666367209732, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1152/ajprenal.00181.2005, pmid=null, pmcid=null, year=2006, volume=290, issue=null, pageStart=F762, pageEnd=F768, url=null, language=null, rfNumber=[73], rfOrder=72, authorNames=null, journalName=Am J Physiol Renal Physiol, refType=null, unstructuredReference=Marrero MB, Banes-Berceli AK, Stern DM, et al. Role of the JAK/STAT signaling pathway in diabetic nephropathy[J]. Am J Physiol Renal Physiol, 2006, 290: F762-F768., articleTitle=Role of the JAK/STAT signaling pathway in diabetic nephropathy, refAbstract=null), Reference(id=1210516666438512903, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1093/ndt/gfx377, pmid=null, pmcid=null, year=2018, volume=33, issue=null, pageStart=1950, pageEnd=1959, url=null, language=null, rfNumber=[74], rfOrder=73, authorNames=null, journalName=Nephrol Dial Transplant, refType=null, unstructuredReference=Tuttle KR, Brosius FC, Adler SG, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial[J]. Nephrol Dial Transplant, 2018, 33: 1950-1959., articleTitle=JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial, refAbstract=null), Reference(id=1210516666547564810, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2018121231, pmid=null, pmcid=null, year=2019, volume=30, issue=null, pageStart=1980, pageEnd=1990, url=null, language=null, rfNumber=[75], rfOrder=74, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Chertow GM, Pergola PE, Chen F, et al. Effects of selonsertib in patients with diabetic kidney disease[J]. J Am Soc Nephrol, 2019, 30: 1980-1990., articleTitle=Effects of selonsertib in patients with diabetic kidney disease, refAbstract=null), Reference(id=1210516666627256589, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1084/jem.178.6.2255, pmid=null, pmcid=null, year=1993, volume=178, issue=null, pageStart=2255, pageEnd=2260, url=null, language=null, rfNumber=[76], rfOrder=75, authorNames=null, journalName=J Exp Med, refType=null, unstructuredReference=Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation[J]. J Exp Med, 1993, 178: 2255-2260., articleTitle=Induction and function of vascular adhesion protein-1 at sites of inflammation, refAbstract=null), Reference(id=1210516666690171150, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2014010028, pmid=null, pmcid=null, year=2015, volume=26, issue=null, pageStart=692, pageEnd=714, url=null, language=null, rfNumber=[77], rfOrder=76, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Ledo N, Ko YA, Park A, et al. Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD[J]. J Am Soc Nephrol, 2015, 26: 692-714., articleTitle=Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD, refAbstract=null), Reference(id=1210516666753085713, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S2213-8587(18)30289-4, pmid=null, pmcid=null, year=2018, volume=6, issue=null, pageStart=925, pageEnd=933, url=null, language=null, rfNumber=[78], rfOrder=77, authorNames=null, journalName=Lancet Diabetes Endocrinol, refType=null, unstructuredReference=de Zeeuw D, Renfurm RW, Bakris G, et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial[J]. Lancet Diabetes Endocrinol, 2018, 6: 925-933., articleTitle=Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial, refAbstract=null), Reference(id=1210516666820194580, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1021/acs.jmedchem.8b02004, pmid=null, pmcid=null, year=2019, volume=62, issue=null, pageStart=4312, pageEnd=4324, url=null, language=null, rfNumber=[79], rfOrder=78, authorNames=null, journalName=J Med Chem, refType=null, unstructuredReference=Pettersen D, Broddefalk J, Emtenas H, et al. Discovery and early clinical development of an inhibitor of 5-lipoxygenase activating protein (AZD5718) for treatment of coronary artery disease[J]. J Med Chem, 2019, 62: 4312-4324., articleTitle=Discovery and early clinical development of an inhibitor of 5-lipoxygenase activating protein (AZD5718) for treatment of coronary artery disease, refAbstract=null), Reference(id=1210516666929246487, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMra071371, pmid=null, pmcid=null, year=2007, volume=357, issue=null, pageStart=1841, pageEnd=1854, url=null, language=null, rfNumber=[80], rfOrder=79, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Peters-Golden M, Henderson WR. Mechanisms of disease: leukotrienes[J]. New Engl J Med, 2007, 357: 1841-1854., articleTitle=Mechanisms of disease: leukotrienes, refAbstract=null), Reference(id=1210516667046687002, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=null, pmid=null, pmcid=null, year=2018, volume=11, issue=null, pageStart=330, pageEnd=338, url=null, language=null, rfNumber=[81], rfOrder=80, authorNames=null, journalName=ClinTransl Sci, refType=null, unstructuredReference=Ericsson H, Nelander K, Lagerstrom-Fermer M, et al. Initial clini-cal experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein inhibitor[J]. ClinTransl Sci, 2018, 11: 330-338., articleTitle=Initial clini-cal experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein inhibitor, refAbstract=null), Reference(id=1210516667126378779, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.atherosclerosis.2014.12.011, pmid=null, pmcid=null, year=2015, volume=238, issue=null, pageStart=220, pageEnd=230, url=null, language=null, rfNumber=[82], rfOrder=81, authorNames=null, journalName=Atherosclerosis, refType=null, unstructuredReference=Pugliese G, Iacobini C, Fantauzzi CB, et al. The dark and bright side of atherosclerotic calcification[J]. Atherosclerosis, 2015, 238: 220-230., articleTitle=The dark and bright side of atherosclerotic calcification, refAbstract=null), Reference(id=1210516667189293341, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2014010093, pmid=null, pmcid=null, year=2015, volume=26, issue=null, pageStart=2213, pageEnd=2221, url=null, language=null, rfNumber=[83], rfOrder=82, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Drechsler C, Delgado G, Wanner C, et al. Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies[J]. J Am Soc Nephrol, 2015, 26: 2213-2221., articleTitle=Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies, refAbstract=null), Reference(id=1210516667298345248, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1080/13543784.2016.1196184, pmid=null, pmcid=null, year=2016, volume=25, issue=null, pageStart=1045, pageEnd=1058, url=null, language=null, rfNumber=[84], rfOrder=83, authorNames=null, journalName=Expert Opin Investig Drug, refType=null, unstructuredReference=Perez-Gomez MV, Sanchez-Nino MD, Sanz AB, et al. Targeting inflammation in diabetic kidney disease: early clinical trials[J]. Expert Opin Investig Drug, 2016, 25: 1045-1058., articleTitle=Targeting inflammation in diabetic kidney disease: early clinical trials, refAbstract=null), Reference(id=1210516667440951588, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2010101049, pmid=null, pmcid=null, year=2011, volume=22, issue=null, pageStart=1144, pageEnd=1151, url=null, language=null, rfNumber=[85], rfOrder=84, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy[J]. J Am Soc Nephrol, 2011, 22: 1144-1151., articleTitle=Pirfenidone for diabetic nephropathy, refAbstract=null), Reference(id=1210516667529031974, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2014121181, pmid=null, pmcid=null, year=2016, volume=27, issue=null, pageStart=439, pageEnd=453, url=null, language=null, rfNumber=[86], rfOrder=85, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Han SH, Malaga-Dieguez L, Chinga F, et al. Deletion of Lkb1 in renal tubular epithelial cells leads to CKD by altering metabolism[J]. J Am Soc Nephrol, 2016, 27: 439-453., articleTitle=Deletion of Lkb1 in renal tubular epithelial cells leads to CKD by altering metabolism, refAbstract=null), Reference(id=1210516667604529448, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1172/JCI66218, pmid=null, pmcid=null, year=2013, volume=123, issue=null, pageStart=4888, pageEnd=4899, url=null, language=null, rfNumber=[87], rfOrder=86, authorNames=null, journalName=J Clin Invest, refType=null, unstructuredReference=Dugan LL, You YH, Ali SS, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function[J]. J Clin Invest, 2013, 123: 4888-4899., articleTitle=AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function, refAbstract=null), Reference(id=1210516667663249704, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.5694/mja2.50239, pmid=null, pmcid=null, year=2019, volume=211, issue=null, pageStart=37, pageEnd=42, url=null, language=null, rfNumber=[88], rfOrder=87, authorNames=null, journalName=Med J Aust, refType=null, unstructuredReference=Tanner C, Wang G, Liu N, et al. Metformin: time to review its role and safety in chronic kidney disease[J]. Med J Aust, 2019, 211: 37-42., articleTitle=Metformin: time to review its role and safety in chronic kidney disease, refAbstract=null), Reference(id=1210516667730358570, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1038/nature12222, pmid=null, pmcid=null, year=2013, volume=499, issue=null, pageStart=43, pageEnd=49, url=null, language=null, rfNumber=[89], rfOrder=88, authorNames=null, journalName=Nature, refType=null, unstructuredReference=Cancer Genome Atlas Research Network. Comprehensive mole-cular characterization of clear cell renal cell carcinoma[J]. Nature, 2013, 499: 43-49., articleTitle=Comprehensive mole-cular characterization of clear cell renal cell carcinoma, refAbstract=null), Reference(id=1210516667810050348, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.3892/mmr.2014.2205, pmid=null, pmcid=null, year=2014, volume=10, issue=null, pageStart=161, pageEnd=168, url=null, language=null, rfNumber=[90], rfOrder=89, authorNames=null, journalName=Mol Med Rep, refType=null, unstructuredReference=Xu HF, Ding YJ, Zhang ZX, et al. MicroRNA-21 regulation of the progression of viral myocarditis to dilated cardiomyopathy[J]. Mol Med Rep, 2014, 10: 161-168., articleTitle=MicroRNA-21 regulation of the progression of viral myocarditis to dilated cardiomyopathy, refAbstract=null), Reference(id=1210516667902325038, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1038/ki.2012.439, pmid=null, pmcid=null, year=2013, volume=83, issue=null, pageStart=1029, pageEnd=1041, url=null, language=null, rfNumber=[91], rfOrder=90, authorNames=null, journalName=Kidney Int, refType=null, unstructuredReference=Ruiz S, Pergola PE, Zager RA, et al. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease[J]. Kidney Int, 2013, 83: 1029-1041., articleTitle=Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease, refAbstract=null), Reference(id=1210516667982016814, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1007/s10157-020-01917-5, pmid=null, pmcid=null, year=2020, volume=24, issue=null, pageStart=857, pageEnd=864, url=null, language=null, rfNumber=[92], rfOrder=91, authorNames=null, journalName=Clin Exp Nephrol, refType=null, unstructuredReference=Kanda H, Yamawaki K. Bardoxolone methyl: drug development for diabetic kidney disease[J]. Clin Exp Nephrol, 2020, 24: 857-864., articleTitle=Bardoxolone methyl: drug development for diabetic kidney disease, refAbstract=null), Reference(id=1210516668053319984, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.cct.2019.105892, pmid=null, pmcid=null, year=2020, volume=90, issue=null, pageStart=105892, pageEnd=null, url=null, language=null, rfNumber=[93], rfOrder=92, authorNames=null, journalName=Contemp Clin Trials, refType=null, unstructuredReference=Reutens AT, Jandeleit-Dahm K, Thomas M, et al. A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: protocol and statistical considerations[J]. Contemp Clin Trials, 2020, 90: 105892., articleTitle=A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: protocol and statistical considerations, refAbstract=null), Reference(id=1210516668128817458, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1080/713609354, pmid=null, pmcid=null, year=2003, volume=40, issue=null, pageStart=209, pageEnd=294, url=null, language=null, rfNumber=[94], rfOrder=93, authorNames=null, journalName=Crit Rev Clin Lab Sci, refType=null, unstructuredReference=Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidyl-peptidase Ⅳ from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP Ⅳ[J]. Crit Rev Clin Lab Sci, 2003, 40: 209-294., articleTitle=Dipeptidyl-peptidase Ⅳ from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP Ⅳ, refAbstract=null), Reference(id=1210516668250452274, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=null, pmid=null, pmcid=null, year=2002, volume=146, issue=null, pageStart=717, pageEnd=727, url=null, language=null, rfNumber=[95], rfOrder=94, authorNames=null, journalName=Eur J Endocrinol, refType=null, unstructuredReference=Reimer MK, Holst JJ, Ahren B. Long-term inhibition of dipeptidyl peptidase Ⅳ improves glucose tolerance and preserves islet function in mice[J]. Eur J Endocrinol, 2002, 146: 717-727., articleTitle=Long-term inhibition of dipeptidyl peptidase Ⅳ improves glucose tolerance and preserves islet function in mice, refAbstract=null), Reference(id=1210516668321755443, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.3803/EnM.2019.34.1.80, pmid=null, pmcid=null, year=2019, volume=34, issue=null, pageStart=80, pageEnd=92, url=null, language=null, rfNumber=[96], rfOrder=95, authorNames=null, journalName=Endocrinol Metab, refType=null, unstructuredReference=Bae JH, Kim S, Park EG, et al. Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis[J]. Endocrinol Metab, 2019, 34: 80-92., articleTitle=Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis, refAbstract=null), Reference(id=1210516668422418740, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1111/dom.12591, pmid=null, pmcid=null, year=2016, volume=18, issue=null, pageStart=203, pageEnd=216, url=null, language=null, rfNumber=[97], rfOrder=96, authorNames=null, journalName=Diabetes Obes Metab, refType=null, unstructuredReference=Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors[J]. Diabetes Obes Metab, 2016, 18: 203-216., articleTitle=Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, refAbstract=null), Reference(id=1210516668531470645, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S0140-6736(02)07952-7, pmid=null, pmcid=null, year=2002, volume=359, issue=null, pageStart=824, pageEnd=830, url=null, language=null, rfNumber=[98], rfOrder=97, authorNames=null, journalName=Lancet, refType=null, unstructuredReference=Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study[J]. Lancet, 2002, 359: 824-830., articleTitle=Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study, refAbstract=null), Reference(id=1210516668640522550, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.semnephrol.2012.06.003, pmid=null, pmcid=null, year=2012, volume=32, issue=null, pageStart=319, pageEnd=326, url=null, language=null, rfNumber=[99], rfOrder=98, authorNames=null, journalName=Semin Nephrol, refType=null, unstructuredReference=Greka A, Mundel P. Calcium regulates podocyte actin dynamics[J]. Semin Nephrol, 2012, 32: 319-326., articleTitle=Calcium regulates podocyte actin dynamics, refAbstract=null), Reference(id=1210516668757963063, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2015030318, pmid=null, pmcid=null, year=2016, volume=27, issue=null, pageStart=2771, pageEnd=2783, url=null, language=null, rfNumber=[100], rfOrder=99, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Riehle M, Buscher AK, Gohlke BO, et al. TRPC6 G757D loss-of-function mutation associates with FSGS[J]. J Am Soc Nephrol, 2016, 27: 2771-2783., articleTitle=TRPC6 G757D loss-of-function mutation associates with FSGS, refAbstract=null), Reference(id=1210516668837654840, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1172/JCI69134, pmid=null, pmcid=null, year=2013, volume=123, issue=null, pageStart=3243, pageEnd=3253, url=null, language=null, rfNumber=[101], rfOrder=100, authorNames=null, journalName=J Clin Invest, refType=null, unstructuredReference=Gee HY, Saisawat P, Ashraf S, et al. ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling[J]. J Clin Invest, 2013, 123: 3243-3253., articleTitle=ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling, refAbstract=null), Reference(id=1210516668921540921, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1172/JCI46458, pmid=null, pmcid=null, year=2011, volume=121, issue=null, pageStart=4127, pageEnd=4137, url=null, language=null, rfNumber=[102], rfOrder=101, authorNames=null, journalName=J Clin Invest, refType=null, unstructuredReference=Akilesh S, Suleiman H, Yu HY, et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis[J]. J Clin Invest, 2011, 121: 4127-4137., articleTitle=Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis, refAbstract=null), Reference(id=1210516668988649786, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1681/ASN.2010050522, pmid=null, pmcid=null, year=2011, volume=22, issue=null, pageStart=526, pageEnd=535, url=null, language=null, rfNumber=[103], rfOrder=102, authorNames=null, journalName=J Am Soc Nephrol, refType=null, unstructuredReference=Eckel J, Lavin PJ, Finch EA, et al. TRPC6 enhances angiotensin Ⅱ-induced albuminuria[J]. J Am Soc Nephrol, 2011, 22: 526-535., articleTitle=TRPC6 enhances angiotensin Ⅱ-induced albuminuria, refAbstract=null), Reference(id=1210516669059952955, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1126/science.aal4178, pmid=null, pmcid=null, year=2017, volume=358, issue=null, pageStart=1332, pageEnd=1336, url=null, language=null, rfNumber=[104], rfOrder=103, authorNames=null, journalName=Science, refType=null, unstructuredReference=Zhou Y, Castonguay P, Sidhom EH, et al. A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models[J]. Science, 2017, 358: 1332-1336., articleTitle=A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models, refAbstract=null), Reference(id=1210516669135450428, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1038/nm.2411, pmid=null, pmcid=null, year=2011, volume=17, issue=null, pageStart=952, pageEnd=970, url=null, language=null, rfNumber=[105], rfOrder=104, authorNames=null, journalName=Nat Med, refType=null, unstructuredReference=Wei CL, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis[J]. Nat Med, 2011, 17: 952-970., articleTitle=Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis, refAbstract=null), Reference(id=1210516669206753597, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1172/JCI124793, pmid=null, pmcid=null, year=2019, volume=129, issue=null, pageStart=1946, pageEnd=1959, url=null, language=null, rfNumber=[106], rfOrder=105, authorNames=null, journalName=J Clin Invest, refType=null, unstructuredReference=Wei CL, Li J, Adair BD, et al. uPAR isoform 2 forms a dimer and induces severe kidney disease in mice[J]. J Clin Invest, 2019, 129: 1946-1959., articleTitle=uPAR isoform 2 forms a dimer and induces severe kidney disease in mice, refAbstract=null), Reference(id=1210516669299028286, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1056/NEJMoa1506027, pmid=null, pmcid=null, year=2016, volume=374, issue=null, pageStart=333, pageEnd=343, url=null, language=null, rfNumber=[107], rfOrder=106, authorNames=null, journalName=New Engl J Med, refType=null, unstructuredReference=Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation[J]. New Engl J Med, 2016, 374: 333-343., articleTitle=Belatacept and long-term outcomes in kidney transplantation, refAbstract=null), Reference(id=1210516669361942847, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=null, pmid=null, pmcid=null, year=2014, volume=2014, issue=null, pageStart=421827, pageEnd=null, url=null, language=null, rfNumber=[108], rfOrder=107, authorNames=null, journalName=J Diabetes Res, refType=null, unstructuredReference=Maile LA, Gollahon K, Wai C, et al. Blocking alpha V beta 3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats[J]. J Diabetes Res, 2014, 2014: 421827., articleTitle=Blocking alpha V beta 3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats, refAbstract=null), Reference(id=1210516669416468800, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.cellsig.2021.110185, pmid=null, pmcid=null, year=2022, volume=90, issue=null, pageStart=110185, pageEnd=null, url=null, language=null, rfNumber=[109], rfOrder=108, authorNames=null, journalName=Cell Signal, refType=null, unstructuredReference=Ookawara M, Nio Y. Phosphodiesterase 4 inhibitors in diabetic nephropathy[J]. Cell Signal, 2022, 90: 110185., articleTitle=Phosphodiesterase 4 inhibitors in diabetic nephropathy, refAbstract=null), Reference(id=1210516669475189057, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1136/bmjopen-2021-053019, pmid=null, pmcid=null, year=2021, volume=11, issue=null, pageStart=e053019, pageEnd=null, url=null, language=null, rfNumber=[110], rfOrder=109, authorNames=null, journalName=BMJ Open, refType=null, unstructuredReference=Leehey DJ, Carlson K, Reda DJ, et al. Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial[J]. BMJ Open, 2021, 11: e053019., articleTitle=Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial, refAbstract=null), Reference(id=1210516669542297922, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.2298/MPNS1606140Z, pmid=null, pmcid=null, year=2016, volume=69, issue=null, pageStart=140, pageEnd=145, url=null, language=null, rfNumber=[111], rfOrder=110, authorNames=null, journalName=Med Pregl, refType=null, unstructuredReference=Zeravica R, Ilincic B, Cabarkapa V, et al. Plasma endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus[J]. Med Pregl, 2016, 69: 140-145., articleTitle=Plasma endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus, refAbstract=null), Reference(id=1210516669601018179, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.diabres.2007.12.024, pmid=null, pmcid=null, year=2008, volume=80, issue=null, pageStart=299, pageEnd=304, url=null, language=null, rfNumber=[112], rfOrder=111, authorNames=null, journalName=Diabetes Res Clin Pract, refType=null, unstructuredReference=Zanatta CM, Gerchman F, Burttet L, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus[J]. Diabetes Res Clin Pract, 2008, 80: 299-304., articleTitle=Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus, refAbstract=null), Reference(id=1210516669680709956, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/S0140-6736(19)30772-X, pmid=null, pmcid=null, year=2019, volume=393, issue=null, pageStart=1937, pageEnd=1947, url=null, language=null, rfNumber=[113], rfOrder=112, authorNames=null, journalName=Lancet, refType=null, unstructuredReference=Heerspink H, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial[J]. Lancet, 2019, 393: 1937-1947., articleTitle=Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial, refAbstract=null), Reference(id=1210516669743624517, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1002/cpt.2143, pmid=null, pmcid=null, year=2021, volume=109, issue=null, pageStart=1631, pageEnd=1638, url=null, language=null, rfNumber=[114], rfOrder=113, authorNames=null, journalName=Clin Pharmacol Ther, refType=null, unstructuredReference=Koomen JV, Stevens J, Bakris G, et al. Individual atrasentan exposure is associated with long-term kidney and heart failure outcomes in patients with type 2 diabetes and chronic kidney disease[J]. Clin Pharmacol Ther, 2021, 109: 1631-1638., articleTitle=Individual atrasentan exposure is associated with long-term kidney and heart failure outcomes in patients with type 2 diabetes and chronic kidney disease, refAbstract=null), Reference(id=1210516669802344774, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1126/science.1193032, pmid=null, pmcid=null, year=2010, volume=329, issue=null, pageStart=841, pageEnd=845, url=null, language=null, rfNumber=[115], rfOrder=114, authorNames=null, journalName=Science, refType=null, unstructuredReference=Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans[J]. Science, 2010, 329: 841-845., articleTitle=Association of trypanolytic ApoL1 variants with kidney disease in African Americans, refAbstract=null), Reference(id=1210516669856870727, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.niox.2018.05.009, pmid=null, pmcid=null, year=2018, volume=78, issue=null, pageStart=72, pageEnd=80, url=null, language=null, rfNumber=[116], rfOrder=115, authorNames=null, journalName=Nitric Oxide, refType=null, unstructuredReference=Buys ES, Zimmer DP, Chickering J, et al. Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential[J]. Nitric Oxide, 2018, 78: 72-80., articleTitle=Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential, refAbstract=null), Reference(id=1210516669932368200, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1016/j.coph.2014.12.014, pmid=null, pmcid=null, year=2015, volume=21, issue=null, pageStart=95, pageEnd=104, url=null, language=null, rfNumber=[117], rfOrder=116, authorNames=null, journalName=Curr Opin Pharmacol, refType=null, unstructuredReference=Stasch JP, Schlossmann J, Hocher B. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence[J]. Curr Opin Pharmacol, 2015, 21: 95-104., articleTitle=Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence, refAbstract=null), Reference(id=1210516669991088457, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.1111/bph.15586, pmid=null, pmcid=null, year=2021, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[118], rfOrder=117, authorNames=null, journalName=Br J Pharmacol, refType=null, unstructuredReference=Stehle D, Xu MZ, Schomber T, et al. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney[J]. Br J Pharmacol, 2021. DOI: 10.1111/bph.15586., articleTitle=Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney, refAbstract=null), Reference(id=1210516670054003018, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, doi=10.2215/CJN.08410520, pmid=null, pmcid=null, year=2021, volume=16, issue=null, pageStart=59, pageEnd=69, url=null, language=null, rfNumber=[119], rfOrder=118, authorNames=null, journalName=Clin J Am Soc Nephrol, refType=null, unstructuredReference=Hanrahan JP, de Boer IH, Bakris GL, et al. Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease a randomized placebo-controlled clinical trial[J]. Clin J Am Soc Nephrol, 2021, 16: 59-69., articleTitle=Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease a randomized placebo-controlled clinical trial, refAbstract=null)], funds=[Fund(id=1210516658637108128, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, awardId=2021-I2M-1-028, language=CN, fundingSource=中国医学科学院医学与健康科技创新工程基金资助(2021-I2M-1-028), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1210516653994013198, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, xref=null, ext=[AuthorCompanyExt(id=1210516654006596113, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1210516654023373330, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516653994013198, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京协和医学院、中国医学科学院药物研究所, 药物传输技术及新型制剂北京市重点实验室, 北京 100050)]), AuthorCompany(id=1210516654186951203, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, xref=null, ext=[AuthorCompanyExt(id=1210516654195339814, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516654186951203, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2. Tianjin University, Tianjin 100072, China), AuthorCompanyExt(id=1210516654203728422, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, companyId=1210516654186951203, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.天津大学, 天津 100072)])], figs=[ArticleFig(id=1210516658326729613, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=EN, label=null, caption=null, figureFileSmall=null, figureFileBig=null, tableContent=

Target		Agent	Disease	Phase	Status
Target inflammation	CCR2	CCX140-B	FSGS	Phase Ⅱ (NCT03703908)	Unknown
			T2D	Phase Ⅱ (NCT01440257)	Completed
		PF-04634817	DN	Phase Ⅱ (NCT01712061)	Completed
	JAK-STAT	Baricitinib	DKD	Phase Ⅱ (NCT01683409)	Completed
			CKD	Phase Ⅱ (NCT05237388)	Not yet recruiting
	ASK1/MAP3K5	Selonsertib (GS-4997)	DKD	Phase Ⅱ (NCT02177786)	Completed
	VAP1/AOC3	ASP8232	CKD/T2D	Phase Ⅱ (NCT02358096)	Completed
	5-LOX	AZD5718	CKD	Phase Ⅱ (NCT04492722)	Recruiting
Target fibrosis	Galectin-3	GCS-100	DKD	Phase Ⅱb (NCT02312050)	Unknown
			CKD	Phase Ⅱ (NCT02155673)	Completed
	TGFβ1	Pirfenidone	CKD	Phase Ⅱ (NCT04258397)	Recruiting
			FSGS/fibrosis	Phase Ⅱ (NCT00001959)	Completed
Target metabolism	AMPK	Metformin	CKD	Phase Ⅱ (NCT02252081)	Completed
			CKD	Phase Ⅲ (NCT03831464)	Recruiting
			ADPKD	Phase Ⅲ (NCT04939935)	Not yet recruiting
	miR-21	Lademirsen	Alport syndrome	Phase Ⅱ (NCT02855268)	Recruiting
	Nrf2	Bardoxolone methyl	Alport syndrome	Phase Ⅱ, Phase Ⅲ (NCT03019185)	Completed
			ADPKD	Phase Ⅲ (NCT03918447)	Recruiting
			DKD	Phase Ⅲ (NCT03550443)	Active, not recruiting
	NOX	GKT137831	T2D with DN	Phase Ⅱ (NCT02010242)	Completed
	DPP4	Linagliptin	T2D/CKD	Not applicable (NCT02608177)	Completed
	GLP-1R	Semaglutide	CKD/DKD	Phase Ⅱ (NCT04741074)	Recruiting
			T2D	Phase Ⅲ (NCT03819153)	Active, not recruiting
Target podocytes	TRPC	GFB-887	DN/FSGS	Phase Ⅱ (NCT04387448)	Recruiting
	αvβ3 integrin	VPI-2690B	DN	Phase Ⅱ (NCT02251067)	Completed
	CD80	Belatacept	Chronic kidney failure	Phase Ⅲ (NCT04013620)	Not yet recruiting
Other targets	PDE	Pentoxifylline	CKD	Phase Ⅲ (NCT05284656)	Enrolling by invitation
			DKD	Phase Ⅳ (NCT03625648)	Recruiting
	ETA	Atrasentan	IgAN/FSGS/Alport syndrome/DKD	Phase Ⅱ (NCT04573920)	Recruiting
	APOL1	VX-147	FSGS	Phase Ⅱ (NCT04340362)	Completed
	KLK1	DM199	Kidney diseases	Phase Ⅱ (NCT04123613)	Recruiting
			CKD	Phase Ⅰ (NCT03795389)	Completed
	sGC	Runcaciguat	DN	Phase Ⅱ (NCT04722991)	Recruiting
			CKD	Phase Ⅱ (NCT04507061)	Active, not recruiting

), ArticleFig(id=1210516658423198612, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210516652110770537, language=CN, label=Table 1, caption=

Drugs with new targets for CKD. FSGS: Focal segmental glomerulosclerosis; T2D: Type 2 diabetes; CKD: Chronic kidney disease; DKD: Diabetic kidney disease; ADPKD: Autosomal dominant polycystic kidney disease; DN: Diabetic nephropathy; IgAN: IgA nephropathy

, figureFileSmall=null, figureFileBig=null, tableContent=

Target		Agent	Disease	Phase	Status
Target inflammation	CCR2	CCX140-B	FSGS	Phase Ⅱ (NCT03703908)	Unknown
			T2D	Phase Ⅱ (NCT01440257)	Completed
		PF-04634817	DN	Phase Ⅱ (NCT01712061)	Completed
	JAK-STAT	Baricitinib	DKD	Phase Ⅱ (NCT01683409)	Completed
			CKD	Phase Ⅱ (NCT05237388)	Not yet recruiting
	ASK1/MAP3K5	Selonsertib (GS-4997)	DKD	Phase Ⅱ (NCT02177786)	Completed
	VAP1/AOC3	ASP8232	CKD/T2D	Phase Ⅱ (NCT02358096)	Completed
	5-LOX	AZD5718	CKD	Phase Ⅱ (NCT04492722)	Recruiting
Target fibrosis	Galectin-3	GCS-100	DKD	Phase Ⅱb (NCT02312050)	Unknown
			CKD	Phase Ⅱ (NCT02155673)	Completed
	TGFβ1	Pirfenidone	CKD	Phase Ⅱ (NCT04258397)	Recruiting
			FSGS/fibrosis	Phase Ⅱ (NCT00001959)	Completed
Target metabolism	AMPK	Metformin	CKD	Phase Ⅱ (NCT02252081)	Completed
			CKD	Phase Ⅲ (NCT03831464)	Recruiting
			ADPKD	Phase Ⅲ (NCT04939935)	Not yet recruiting
	miR-21	Lademirsen	Alport syndrome	Phase Ⅱ (NCT02855268)	Recruiting
	Nrf2	Bardoxolone methyl	Alport syndrome	Phase Ⅱ, Phase Ⅲ (NCT03019185)	Completed
			ADPKD	Phase Ⅲ (NCT03918447)	Recruiting
			DKD	Phase Ⅲ (NCT03550443)	Active, not recruiting
	NOX	GKT137831	T2D with DN	Phase Ⅱ (NCT02010242)	Completed
	DPP4	Linagliptin	T2D/CKD	Not applicable (NCT02608177)	Completed
	GLP-1R	Semaglutide	CKD/DKD	Phase Ⅱ (NCT04741074)	Recruiting
			T2D	Phase Ⅲ (NCT03819153)	Active, not recruiting
Target podocytes	TRPC	GFB-887	DN/FSGS	Phase Ⅱ (NCT04387448)	Recruiting
	αvβ3 integrin	VPI-2690B	DN	Phase Ⅱ (NCT02251067)	Completed
	CD80	Belatacept	Chronic kidney failure	Phase Ⅲ (NCT04013620)	Not yet recruiting
Other targets	PDE	Pentoxifylline	CKD	Phase Ⅲ (NCT05284656)	Enrolling by invitation
			DKD	Phase Ⅳ (NCT03625648)	Recruiting
	ETA	Atrasentan	IgAN/FSGS/Alport syndrome/DKD	Phase Ⅱ (NCT04573920)	Recruiting
	APOL1	VX-147	FSGS	Phase Ⅱ (NCT04340362)	Completed
	KLK1	DM199	Kidney diseases	Phase Ⅱ (NCT04123613)	Recruiting
			CKD	Phase Ⅰ (NCT03795389)	Completed
	sGC	Runcaciguat	DN	Phase Ⅱ (NCT04722991)	Recruiting
			CKD	Phase Ⅱ (NCT04507061)	Active, not recruiting

)], attaches=null, journal=Journal(id=1189982048455397383, delFlag=0, nameCn=药学学报, nameEn=Acta Pharmaceutica Sinica, nameHistory1=null, nameHistory2=null, issn=0513-4870, eissn=null, cn=11-2163/R, coden=null, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=BTxjudbJDVO4PqdBR6On6Q==, journalPrice=null, startedYear=null, abbrevIsoEn=null, journalRemark=null, publicationField=null, createdTime=1761643429151, updatedTime=1761735768113, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=A, firstLetterEn=A, subjectCode=Life Sciences, subjectName=Life Sciences, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=BTxjudbJDVO4PqdBR6On6Q==, picEn=c4l1ckL55nWbhl1KrFdWIA==, jcr=null, cjcr=null, exts=[JournalExt(id=1190369346338783397, language=CN, name=药学学报, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735768160, updatedTime=1761735768160, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://www.yxxb.com.cn/journalx_yxxb/authorLogOn.action, submissionEditorUrl=https://www.yxxb.com.cn/journalx_yxxb/editorLogOn.action, submissionReviewUrl=https://www.yxxb.com.cn/journalx_yxxb/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1190369346376532134, language=EN, name=Acta Pharmaceutica Sinica, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735768169, updatedTime=1761735768169, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://www.yxxb.com.cn/journalx_yxxb/authorLogOn.action, submissionEditorUrl=https://www.yxxb.com.cn/journalx_yxxb/editorLogOn.action, submissionReviewUrl=https://www.yxxb.com.cn/journalx_yxxb/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1189982191388893191, websiteList=[Website(id=1189982271588340489, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189982191388893191, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/yxxb/CN, language=CN, createTime=1761643482348, createBy=18614031015, updateTime=1761643498101, updateBy=18614031015, name=药学学报-中文, tplId=1146099689490845704, title=药学学报, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189982873114448678, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=articleTextType, value=kx, createTime=1761643625763, updateTime=1761643625763, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873093477155, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=banner, value=null, createTime=1761643625758, updateTime=1761643625758, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873135420201, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=grayFlag, value=0, createTime=1761643625768, updateTime=1761643625768, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873085088546, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=logo, value=https://castjournals.cast.org.cn/joweb/yxxb/CN/file/pic?fileId=w+t2v8bJnX5lh3+hRRJcDA==, createTime=1761643625756, updateTime=1761643625756, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873152197419, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=minRunFlag, value=0, createTime=1761643625772, updateTime=1761643625772, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873110254373, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/yxxb/CN/file/pic, createTime=1761643625762, updateTime=1761643625762, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873143808810, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=silenceFlag, value=0, createTime=1761643625770, updateTime=1761643625770, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873101865764, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1761643625760, updateTime=1761643625760, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873122837287, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=themeColor, value=null, createTime=1761643625765, updateTime=1761643625765, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873127031592, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=themeStyle, value=null, createTime=1761643625766, updateTime=1761643625766, creator=18614031015, updator=18614031015)]), Website(id=1189982271655449355, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189982191388893191, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/yxxb/EN, language=EN, createTime=1761643482364, createBy=18614031015, updateTime=1761643514085, updateBy=18614031015, name=药学学报-英文, tplId=1146101810881728533, title=Acta Pharmaceutica Sinica, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189982903015633534, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=articleTextType, value=kx, createTime=1761643632892, updateTime=1761643632892, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902990467707, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=banner, value=null, createTime=1761643632886, updateTime=1761643632886, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903036605057, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=grayFlag, value=0, createTime=1761643632897, updateTime=1761643632897, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902982079098, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=logo, value=https://castjournals.cast.org.cn/joweb/yxxb/EN/file/pic?fileId=w+t2v8bJnX5lh3+hRRJcDA==, createTime=1761643632884, updateTime=1761643632884, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903053382275, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=minRunFlag, value=0, createTime=1761643632901, updateTime=1761643632901, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903007244925, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/yxxb/EN/file/pic, createTime=1761643632890, updateTime=1761643632890, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903044993666, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=silenceFlag, value=0, createTime=1761643632899, updateTime=1761643632899, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902998856316, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1761643632888, updateTime=1761643632888, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903019827839, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=themeColor, value=null, createTime=1761643632893, updateTime=1761643632893, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903028216448, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=themeStyle, value=null, createTime=1761643632895, updateTime=1761643632895, creator=18614031015, updator=18614031015)])], journalTitle=药学学报, weixinUrl=null, journalUrl=https://www.yxxb.com.cn/aps, iacademicId=null, status=1, seqNo=null, journalTitleEn=Acta Pharmaceutica Sinica, journalPhotoCn=BTxjudbJDVO4PqdBR6On6Q==, journalPhotoEn=c4l1ckL55nWbhl1KrFdWIA==, journalFirstLetter=A, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false), detailUrlCn=https://castjournals.cast.org.cn/joweb/yxxb/CN/10.16438/j.0513-4870.2022-0134, detailUrlEn=https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0134, pdfUrlCn=https://castjournals.cast.org.cn/joweb/yxxb/CN/PDF/10.16438/j.0513-4870.2022-0134, pdfUrlEn=https://castjournals.cast.org.cn/joweb/yxxb/EN/PDF/10.16438/j.0513-4870.2022-0134, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, reference=null)